H. pylori Infection: Diagnosis, Treatment, and Who Should Be Tested

While the prevalence of *H. pylori* infection has decreased in recent years in North America, this globally prevalent bacterium remains a significant health concern. Understanding *H. pylori* infection is crucial for healthcare professionals to effectively diagnose and manage patients at risk.

**What is *H. pylori*?**

*H. pylori* is a chronic bacterial infection that affects the stomach lining. While many infected individuals experience no symptoms, *H. pylori* can lead to various gastrointestinal issues, including:

* Peptic ulcer disease
* Marginal zone B-cell lymphoma
* Gastric adenocarcinoma
* Dyspepsia (indigestion)
* Idiopathic thrombocytopenic purpura
* Unexplained iron deficiency

Recent research suggests that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), including low-dose aspirin, may increase the risk of *H. pylori* infection.

**Who Needs Testing?**

The American College of Gastroenterology (ACG) provides comprehensive guidelines for *H. pylori* testing and treatment. They recommend testing:

* Individuals with symptoms suggestive of *H. pylori* infection, such as peptic ulcers, dyspepsia, or chronic gastritis.
* Patients at high risk for gastric adenocarcinoma, including those with autoimmune gastritis, a history of premalignant conditions, or a first-degree relative with gastric cancer.
* Household members of individuals who test positive for *H. pylori*.

**Treatment Options**

For individuals diagnosed with *H. pylori* infection, the ACG recommends a 14-day treatment course. Effective regimens often include:

* **Bismuth quadruple therapy:** This is the preferred first-line treatment for treatment-naive patients without penicillin allergy. It consists of a proton pump inhibitor (PPI), bismuth subcitrate or subsalicylate, tetracycline, and metronidazole.
* **Rifabutin-based triple therapy:** A combination of omeprazole, amoxicillin, and rifabutin.
* **PCAB-based regimens:** Dual or triple therapy with vonoprazan, a potassium-competitive acid blocker. This may offer advantages over standard PPI-based regimens, particularly in patients with certain genetic variations.

**Important Considerations**

* Treatment compliance is crucial for successful eradication.
* Antibiotic susceptibility testing is essential to choose the most effective treatment regimen.
* Maintaining gastric acid suppression with a PPI is critical for the success of *H. pylori* eradication.

**H. pylori management is complex, and tailored treatment plans are essential for optimal outcomes. Always consult with a healthcare professional for personalized guidance and to stay informed about the latest recommendations.**